Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9707256
Methods of making endothelial scaffolds
granted -
US 9708359
Pyrrolopyrimidine nucleosides and analogs thereof
granted -
US 9708247
Modulators of the eIF2alpha pathway
granted -
US 9707284
Formulations of peptides and chloroquines for the treatment of pathogenic immune responses in immune mediated diseases
granted -
US 9707210
Methods of treating muscular dystrophy
granted -
US 9700492
Dental composites systems and methods of making the same and using same
granted -
US 9701758
Anti-CD19 scFv (FMC63) polypeptide
granted -
US 9701792
Composite compositions and methods of preparing and using same
granted -
US 9701706
Pyrrolopyrimidine nucleosides and analogs thereof
granted -
US 9701675
Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
granted -
US 9701676
Pro-neurogenic compounds
granted -
US 9700600
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
granted -
US 9700601
Compositions and methods for the treatment of lysosomal storage disorders
granted -
US 9700620
Polymeric nanocarriers with light-triggered release mechanism
granted -
US 9700583
Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
granted -
US 9700519
Spray dry method for encapsulation of biological moieties and chemicals in polymers cross-linked by multivalent ions for controlled release applications
granted -
US 9700509
Solutions of lipophilic substances, especially medicinal solutions
granted -
US 9701713
Compositions and methods for introduction of macromolecules into cells
granted -
US 9700596
Locally released growth factors to mediate motor recovery after stroke
granted -
US 9700628
Heparin-mimicking sulfonated reverse thermal gel for the delivery of heparin-binding therapeutic proteins
granted -
US 9700708
Maintaining multiple defined physiological zones using model predictive control
granted -
US 9694049
Methods for treating muscular dystrophy
granted -
US 9693999
Small molecule RNase inhibitors and methods of use
granted -
US 9695251
Activatable cell penetrating peptides with quenched fluorophores
granted -
US 9695246
Anti-OX40 antibodies and methods of using the same
granted -
US 9695229
Compositions of, and methods for, alpha-1 antitrypsin Fc fusion molecules
granted -
US 9695223
Engineered xylose transporters with reduced glucose inhibition
granted -
US 9695249
Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
granted -
US 9695153
Oligooxopiperazines for p53 reactivation
granted -
US 9694074
Functionalized porous silicon nanoparticles and use thereof in photodynamic therapy
granted -
US 9694047
Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP)
granted -
US 9687559
Heparosan polymers and methods of making and using same for the enhancement of therapeutics
granted -
US 9688673
Deoxycytidine kinase binding compounds
granted -
US 9687553
Polymeric nanocarriers with linear dual response mechanism
granted -
US 9687527
Stable glucagon formulations for the treatment of hypoglycemia
granted -
US 9689042
Use of glycolytic pathways for inhibiting or measuring oncogenic signaling
granted -
US 9687551
Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
granted -
US 9688722
Substrates and inhibitors of prolyl oligopeptidase and methods of use
granted -
US 9682151
Peptides whose uptake in cells is controllable
granted -
US 9682106
Method for combined conditioning and chemoselection in a single cycle
granted -
US 9683009
Bone-selective osteogenic oxysterol-bone targeting agents
granted -
US 9683025
Methods and compositions for treating cancer and inflammatory diseases
granted -
US 9675662
Compositions for inhibition of RNA polymerase I and methods of production and use thereof
granted -
US 9678060
Lunasin-induced regulation of disease-related gene expression
granted -
US 9675697
BET bromodomain inhibitors and therapeutic methods using the same
granted -
US 9675649
Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
granted -
US 9675633
miRNA for treating cancer and for use with adoptive immunotherapies
granted -
US 9675663
TUSC2 therapies
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory